The Food and Drug Administration (FDA) is seeking public comment on potential new standards for in-home opioid disposal products, part of the agency’s effort to address the opioid crisis.

Reminder: Companies selling opioid analgesics are currently required to make available prepaid mail-back envelopes to outpatient pharmacies and other dispensers.

But now: FDA is considering whether to require opioid sponsors, through dispensers, to make available in-home disposal systems.

The details: The Request for Information seeks input from industry, health care providers, and advocates on appropriate criteria for in-home disposal kits.

• This aligns with the SUPPORT Reauthorization Act, which requires FDA to issue guidance to facilitate in-home safe disposal.